Navigation Links
Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
Date:8/27/2010

s. In the other study of 484 patients, the treatment difference between Tekamlo and amlodipine was 7.1/3.8 mmHg at endpoint.

The single-pill combination Tekamlo works to lower blood pressure in two ways. The Tekturna component targets the activity of the renin angiotensin aldosterone system (RAAS), an important regulator of blood pressure. Tekturna directly binds to and inhibits renin, an enzyme produced by the kidneys that starts a process that can make blood vessels narrow and lead to high blood pressure. The calcium channel blocker amlodipine lowers blood pressure by relaxing the blood vessel walls through the inhibition of calcium. Both of these medicines enable blood to flow more easily therefore lowering blood pressure. The blood pressure lowering effects of Tekamlo are largely attained within one to two weeks.

"Single-pill combination therapies provide a convenient treatment option while supporting physicians in addressing the complex needs of patients," said Alan H. Gradman, M.D., Professor of Medicine at Temple University School of Medicine. "This new single-pill combination demonstrated greater blood pressure reductions than either drug alone in clinical studies and therefore provides a new option to consider when choosing appropriate high blood pressure therapies."

Nearly 75 million -- or one in three -- US adults have hypertension. If left untreated, high blood pressure can lead to stroke, heart attack and heart failure. Tekamlo is not approved to treat or prevent stroke, heart attack and heart failure.

Of US adults being treated with high blood pressure medications, an estimated 31 percent do not have their blood pressure controlled to the recommended target of <140/90 mmHg. Research suggests that up to 85 percent of patients may need multiple medicines to achieve target levels of blood pressure control.

Novartis and Hypertension ManagementFor decades Novartis has been a leader and innovator in hypertension mana
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Iliad Neurosciences, Inc., ... to diagnosing and treating Autism Spectrum Disorders (ASD) announced ... Agreement with The Research Foundation for The State University ... will provide a new biomarker to identify an abnormality ... to ASD. This biomarker is expected to be available ...
(Date:9/18/2014)... MEETING, Pa. , Sept. 18, 2014 ... trial solutions, was recognized as the Disruptive ... for its ePharmaONE cloud-based eClinical platform. This ... and electronic trial master file (eTMF), a ... solution, and ePharmaSolutions, ReferralPlus+ patient screening and ...
(Date:9/18/2014)... YORK and PLAINSBORO, N.J. ... announced today its support of the National Hemophilia ... Care , which provides support to people with ... physical and psychosocial challenges that can impede disease ... six modules, Communication With Your Provider About ...
Breaking Medicine Technology:Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3
... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today ... in patients with non-small cell lung cancer has ... multi-center, monotherapy,study of KOS-1584 in patients with measurable ... previously received only one prior,chemotherapy regimen. The primary ...
... SAN DIEGO, April 13 Researchers from ... today presented findings,showing that adding curcumin or ... preventing the growth of chemo-resistant colon cancer,cells. ... American Association,for Cancer Research (AACR) Annual Meeting ...
Cached Medicine Technology:Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer 2Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer 3Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer 4Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells 2
(Date:9/18/2014)... It is that time of year – ... Once again, Evensong Spa at Heidel House ... services at a special $50 rate Oct. 20 through Nov. ... Hotels & Resorts , is the only Wisconsin destination spa ... embrace health and wellness by experiencing affordable spa and wellness ...
(Date:9/18/2014)... Study after study has proven it true: exercise is ... Pennsylvania scientists suggests that exercise may have an added ... performed in a mouse model of melanoma, found that ... alone. , Joseph Libonati, an associate professor in ... of Innovative and Translational Nursing Research, was the senior ...
(Date:9/18/2014)... Lake City, UT (PRWEB) September 18, 2014 ... North America will be recognizing their shared fundraising impact ... on Thursday, Sept. 25. , The first-ever Dance Marathon ... more than $20 million projected to be raised by ... their community’s CMN Hospital. Donations generated through Dance Marathon ...
(Date:9/18/2014)... -- don,t worry, it,s a good thing! As scientists ... are bad. Many active enzymes and bacteria are merely ... an important part of our digestive system or can ... , an opportunistic yeast pathogen and model organism for ... personal ecosystem. However, when our immune system is stressed ...
(Date:9/18/2014)... ANGELES (September 18, 2014) The National Institutes ... funding from a four-year, $1.3 million grant to the ... in the research and development of a vaccine to ... and Methicillin-resistant Staphylococcus aureus (MRSA). , ... of the NIH awarded the grant to LA BioMed ...
Breaking Medicine News(10 mins):Health News:Evensong Spa Celebrates Spa Week with $50 Services 2Health News:Evensong Spa Celebrates Spa Week with $50 Services 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2
... Use of anesthesia providers to monitor sedation during screening ... from 2003 to 2009 in the United States, with ... not need this service, according to a new RAND ... as $1.1 billion spent annually on anesthesia services for ...
... March 20 (HealthDay News) -- Calculating the difference ... right arms might help predict a patient,s odds of ... Researchers found that people with high blood pressure whose ... higher risk of cardiovascular death over 10 years. ...
... (HealthDay News) -- The northeastern United States may see a significant ... The reason is that oak trees produced relatively few acorns ... years for the acorn crop. But the small crop means trouble ... had a boom in acorns, followed by a boom in mice. ...
... Reporter , TUESDAY, March 20 (HealthDay News) -- ... own stem cells may someday replace or reduce the ... Six months after receiving a kidney transplant, only ... stem cells experienced rejection compared with almost 22 percent ...
... failure and endocrine tumors are among the suspects causing ... relievers in your medicine cabinet be the culprit? ... Sackler Faculty of Medicine and the Sheba Medical Center, ... of hypertension, which is a major risk factor for ...
... March 20 (HealthDay News) -- Seeing a baby,s face triggers ... reward and planning movement, a finding researchers say may indicate ... Researchers observed this pattern in adults who didn,t know the ... "These adults have no children of their own. Yet images ...
Cached Medicine News:Health News:Use of anesthesia providers during GI procedures is growing, but may be unnecessary 2Health News:Blood Pressure Variance Between Arms Points to Heart Risk 2Health News:Northeast U.S. Should Brace for Spike in Lyme Disease: Expert 2Health News:Stem Cell Therapy Could Boost Kidney Transplant Success: Study 2Health News:Stem Cell Therapy Could Boost Kidney Transplant Success: Study 3Health News:Stem Cell Therapy Could Boost Kidney Transplant Success: Study 4Health News:Pain relievers could be spiking your blood pressure 2Health News:Infants' Faces Trigger Caregiving Impulse in Adults' Brains 2
... Flexible biopsy forceps are extremely delicate ... incompetent repair source, they can easily be ... turn, damage your endoscopes. , On the ... flexible biopsy forceps can have a virtually ...
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
... With our factory-quality repairs, physicians know ... why more hospitals turn to Mobile Instrument ... We offer a full line of carbide ... our four-way quality control process. You'll enjoy ...
Inquire...
Medicine Products: